SANTEN PHARMACEUTICAL CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1890-01-01
- Employees
- 3.7K
- Market Cap
- $4.5B
- Website
- http://www.santen.co.jp
Clinical Trials
102
Trial Phases
6 Phases
Drug Approvals
50
Drug Approvals
Vitamin B12 Eye Drops
- Product Name
- 维生素B12滴眼液
- Approval Number
- 国药准字HJ20150389
- Approval Date
- Jul 23, 2024
Vitamin B12 Eye Drops
- Product Name
- 维生素B12滴眼液
- Approval Number
- 国药准字HJ20150390
- Approval Date
- Jul 23, 2024
Sodium Hyaluronate Eye Drops
- Product Name
- 爱丽
- Approval Number
- 国药准字HJ20130585
- Approval Date
- Apr 25, 2023
Sodium Hyaluronate Eye Drops
- Product Name
- 爱丽
- Approval Number
- 国药准字HJ20130583
- Approval Date
- Apr 25, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
Clinical Trials
Distribution across different clinical trial phases (85 trials with phase data)• Click on a phase to view related trials
A Pharmacokinetics (PK) Study in Healthy Adults
- Conditions
- Blepharoptosis
- Interventions
- Drug: STN1013800 ophthalmic solution
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT06911216
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
A Study in Chinese Patients With Acquired Blepharoptosis
- Conditions
- Blepharoptosis
- Interventions
- Drug: STN1013800 ophthalmic solutionDrug: STN1013800 ophthalmic solution Liquid Base, without STN1013800
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06683651
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 338
- Registration Number
- NCT06666855
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, China
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers
- Conditions
- Healthy Adult Males Volunteers
- Interventions
- Drug: STN1012600 ophthalmic solution 0.002%
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05905653
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan
A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Drug: STN1012600 ophthalmic solution 0.002%Drug: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Target Recruit Count
- 131
- Registration Number
- NCT05503901
- Locations
- 🇯🇵
Kitanagoya Eye Clinic, Aichi, Japan
🇯🇵Miyake Eye Hospital, Aichi, Japan
🇯🇵Nagasaka Eye Clinic, Aichi, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
RemeGen and Santen Strike $1.3 Billion Licensing Deal for Dual-Target Ophthalmic Drug RC28-E
RemeGen has entered into an exclusive licensing agreement with Santen Pharmaceutical for RC28-E, a VEGF/FGF dual-target fusion protein drug for ocular neovascular diseases, with potential payments totaling up to RMB 1.295 billion ($180 million USD).